Sorivudine topical
Alternative Names: ARYS-01; JA-001Latest Information Update: 27 May 2015
At a glance
- Originator aRigen
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Herpes zoster
Most Recent Events
- 22 May 2009 Sorivudine topical is no longer licensed to Janus Pharmaceuticals (now Topica Pharmaceuticals) in USA
- 20 Feb 2007 Interim results from a phase II trial in patients with Herpes zoster added to the adverse events and Viral Infections therapeutic trials sections
- 07 Dec 2006 Final results from a phase II clinical trial (ARYS-0502) for Herpes zoster added to the Viral Infections therapeutic trials section